--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-223071" form_type: "8-K" ticker: "MREO" cik: "0001719714" company_name: "Mereo BioPharma Group plc" filed_at: "2026-05-14T14:22:48+00:00" generated_at: "2026-05-14T14:25:35.385131+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.15 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Mereo BioPharma shareholders approve all 11 resolutions at 2026 AGM ## Summary - 436,766,255 ordinary shares represented at the May 14, 2026 AGM. - Directors Justin Roberts, Dr. Daniel Shames, and Marc Yoskowitz re-elected with >93% support each. - Directors' remuneration policy approved with 91.74% of votes for. - Authorization to allot shares up to £3,591,354.73 passed with 80.54% for, valid until June 30, 2029. - All resolutions including auditor reappointment and advisory say-on-pay passed. ## SEC filing metadata - accession: 0001193125-26-223071 - form_type: 8-K - ticker: MREO - cik: 0001719714 - company_name: Mereo BioPharma Group plc - filed_at: 2026-05-14T14:22:48+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.15 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/mreo-20260514.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-223071 - JSON: https://secwatch.observer/filing/0001193125-26-223071.json - Plain text: https://secwatch.observer/filing/0001193125-26-223071.txt ## Key facts - Shareholder Votes Mereo BioPharma Group plc shareholders approved Approval of directors' remuneration policy at the 2026-05-14 meeting. - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 5 That the directors’ remuneration policy as set out in the Company’s annual report and accounts for the year ended December 31, 2025, which takes effect from the end of the annual general meeting, be approved. Vote for % of shares voted Votes against % of shares voted Votes withheld 290,456,675 91.74% 26,150,725 8.26% 120,158,855 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Re-election of directors at the 2026-05-14 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 7 That Justin Roberts be re-appointed as a director of the Company. Vote for % of shares voted Votes against % of shares voted Votes withheld 295,886,535 93.77% 19,670,940 6.23% 121,208,780 Resolution 8 That Dr. Daniel Shames be re-appointed as a director of the Company. Vote for % of shares voted Votes against % of shares voted Votes withheld 297,469,530 94.27% 18,085,670 5.73% 121,211,055 Resolution 9 That Marc Yoskowitz be re-appointed as a director of the Company. Vote for % of shares voted Votes against % of shares voted Votes withheld 297,750,480 94.32% 17,929,525 5.68% 121,086,250 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Authorization of Audit and Risk Committee to determine auditors' remuneration at the 2026-05-14 meeting. - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 3 That the Audit and Risk Committee be authorized to determine PwC’s remuneration for the fiscal year ending December 31, 2026. Vote for % of shares voted Votes against % of shares voted Votes withheld 311,313,685 98.22% 5,656,600 1.78% 119,795,970 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-14 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 6 That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis. Vote for % of shares voted Votes against % of shares voted Votes withheld 290,149,130 91.71% 26,223,920 8.29% 120,393,205 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Authorization to allot shares for cash on non-pre-emptive basis at the 2026-05-14 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 11 That, subject to Resolution 10 being passed, the Directors are authorized to allot shares for cash on a non-pre-emptive basis up to a maximum nominal amount of £3,591,354.73. The authority set out in Resolution 11 will expire on June 30, 2029. Vote for % of shares voted Votes against % of shares voted Votes withheld 254,938,500 80.59% 61,391,160 19.41% 120,436,595 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Re-appointment of PricewaterhouseCoopers LLP as auditors at the 2026-05-14 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 2 That PricewaterhouseCoopers LLP (“PwC”) be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company’s annual report and accounts are presented. Vote for % of shares voted Votes against % of shares voted Votes withheld 429,804,470 98.59% 6,156,620 1.41% 805,165 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Authorization to allot shares at the 2026-05-14 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 10 That the Directors are authorized in accordance with section 551 of the Companies Act 2006 to allot shares in the Company and to grant rights to subscribe for or convert any security into shares in the Company up to a maximum nominal amount of £3,591,354.73. The authority set out in Resolution 10 will expire on June 30, 2029 and would replace the existing authority granted at the general meeting of the Company held on May 22, 2023 to the extent not utilized at the date this Resolution is passed. Vote for % of shares voted Votes against % of shares voted Votes withheld 254,728,730 80.54% 61,529,760 19.46% 120,507,765 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Approval of directors' remuneration report at the 2026-05-14 meeting. - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 4 That the directors’ remuneration report (excluding the directors’ remuneration policy), as set out in the Company’s annual report and accounts for the year ended December 31, 2025, be approved. Vote for % of shares voted Votes against % of shares voted Votes withheld 295,564,225 93.35% 21,038,465 6.65% 120,163,565 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm - Shareholder Votes Mereo BioPharma Group plc shareholders approved Adoption of annual report and accounts at the 2026-05-14 meeting. - Outcome: passed - Meeting: 2026-05-14 source text: Resolution 1 That the annual report and accounts for the year ended December 31, 2025, together with the directors’ report and independent auditor’s report thereon, be received and adopted. Vote for % of shares voted Votes against % of shares voted Votes withheld 311,388,645 98.29% 5,412,060 1.71% 119,965,550 evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526223071/0001193125-26-223071-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.